Pfizer Strengthens Outlook as Cost Discipline and Drug Portfolio Revive Investor Confidence
Pfizer has lifted its 2025 profit forecast for the second consecutive quarter, signaling renewed financial stability and strategic resilience after a turbulent period marked by waning pandemic-era sales. The upward revision underscores how the U.S. pharmaceutical giant is navigating its post-COVID transition through disciplined cost management, robust performance of key therapies, and targeted product launches…









